Supporting the Physiatrist, Strengthening the Specialty

AAPM&R is working to ensure PM&R is positioned to thrive in the future of healthcare and that you’re prepared for wherever your career takes you. Our more than 10,000 Academy members support each other in advancing PM&R’s impact through healthcare. As we move forward, it is more important than ever that every member play an active role in helping one another realize the vision for our specialty.

Newsroom

Looking for AAPM&R members in the news? Press releases? Our Academy Action Center? Or looking to submit your members in the news content? You'll find it all in our Newsroom. You will also be able to explore PM&R and Academy news as well as learn how to contact us if you would like to submit your member content, or if you are a reporter who is interested in speaking with a PM&R physician.

Event Calendar and Webinars

Stay up to date on all Academy events and learning opportunities and view recordings of past webinars. 

PM&R Aspire

PM&R Aspire is our career-exploration platform purpose-built to help PM&R professionals make better-informed career decisions. We have mapped employer locations across the United States, enabling you to explore, message and apply to the roles that matter most to you.

PM&R Q&A Video Conversations

AAPM&R is leading the advancement of physiatry’s impact throughout healthcare as aligned with YOUR vision for the specialty. Explore our Q&A video series where members of our Physiatrist in Training (PHiT) Council Board chat with AAPM&R Board leaders.

Latest News

UPDATE: Voluntary Recall of Synvisc-One Lot 7RSL021

Dec 20, 2017, 12:19 by User Not Found

UPDATE (Jan. 2, 2018): No other Synvisc-One or SYNVISC lots are impacted by this voluntary recall. This voluntary product recall is isolated to one product lot within the US only and is at the physician, hospital, and wholesale/pharmacy level. Read this letter for further details and contact information.

Originally published on December 20, 2017:

On December 11, 2017, Sanofi Genzyme initiated a voluntary product recall for a single lot of Synvisc-One® (hylan G-F 20) lot 7RSL021 due to an ongoing investigation which revealed the presence of microbial contamination. The microbe is a common airborne organism and is a rare cause of human infections in both immunocompromised and immunocompetent patients. 

Use of this voluntarily recalled lot may result in a risk of infection. This lot was distributed October 25, 2017 through November 7, 2017 only in the US market. The most frequently reported adverse events in association with this lot are consistent with documented adverse events in the product label. This voluntary recall is being conducted with the knowledge of the US Food and Drug Administration. 

No other Synvisc-One or Synvisc lots are impacted by this voluntary recall. The voluntary recall is at the physician and wholesale/pharmacy level and is isolated to one product lot. 

Sanofi Genzyme is working with its distributors to ensure that all product in the specified lot is returned to the company. Sanofi Genzyme is committed to patient safety and to maintaining the highest product quality standards and we do not anticipate supply issues for Synvisc-One as a result of this voluntary product recall. 

For More Information: 

Health Care Providers should direct all medical and clinical questions to Sanofi Medical Information Services in the U.S. at 1-800-633-1610, option 1. 

Patient inquiries regarding this voluntary recall should be directed to Sanofi U.S. Customer Service at 1-800-633-1610 option 7 then 4. 

Patients who have experienced an adverse event or for Health Care Providers reporting an adverse event, all calls should be directed to Sanofi Adverse Event Reporting in the U.S. at 1-800-633-1610, option 2. 

General Questions about the voluntary recall should be directed to Sanofi U.S. Customer Service at 1-800-633-1610 option 7 then 4. 

For product return information related to the voluntary recalled Synvisc-One lot 7RSL021, please contact FedEx Supply Chain Solutions (GENCO) at 1-855-838-5782.

UPDATE: Voluntary Recall of Synvisc-One Lot 7RSL021

Dec 20, 2017, 12:19 by User Not Found

UPDATE (Jan. 2, 2018): No other Synvisc-One or SYNVISC lots are impacted by this voluntary recall. This voluntary product recall is isolated to one product lot within the US only and is at the physician, hospital, and wholesale/pharmacy level. Read this letter for further details and contact information.

Originally published on December 20, 2017:

On December 11, 2017, Sanofi Genzyme initiated a voluntary product recall for a single lot of Synvisc-One® (hylan G-F 20) lot 7RSL021 due to an ongoing investigation which revealed the presence of microbial contamination. The microbe is a common airborne organism and is a rare cause of human infections in both immunocompromised and immunocompetent patients. 

Use of this voluntarily recalled lot may result in a risk of infection. This lot was distributed October 25, 2017 through November 7, 2017 only in the US market. The most frequently reported adverse events in association with this lot are consistent with documented adverse events in the product label. This voluntary recall is being conducted with the knowledge of the US Food and Drug Administration. 

No other Synvisc-One or Synvisc lots are impacted by this voluntary recall. The voluntary recall is at the physician and wholesale/pharmacy level and is isolated to one product lot. 

Sanofi Genzyme is working with its distributors to ensure that all product in the specified lot is returned to the company. Sanofi Genzyme is committed to patient safety and to maintaining the highest product quality standards and we do not anticipate supply issues for Synvisc-One as a result of this voluntary product recall. 

For More Information: 

Health Care Providers should direct all medical and clinical questions to Sanofi Medical Information Services in the U.S. at 1-800-633-1610, option 1. 

Patient inquiries regarding this voluntary recall should be directed to Sanofi U.S. Customer Service at 1-800-633-1610 option 7 then 4. 

Patients who have experienced an adverse event or for Health Care Providers reporting an adverse event, all calls should be directed to Sanofi Adverse Event Reporting in the U.S. at 1-800-633-1610, option 2. 

General Questions about the voluntary recall should be directed to Sanofi U.S. Customer Service at 1-800-633-1610 option 7 then 4. 

For product return information related to the voluntary recalled Synvisc-One lot 7RSL021, please contact FedEx Supply Chain Solutions (GENCO) at 1-855-838-5782.

Explore AAPM&R

Online Learning Portal

Education is a fundamental offering that affects PM&R physicians across clinical focuses, practice areas, career stages and levels of expertise. As part of Academy membership, we provide top-notch education and other innovative learning resources across a variety of delivery mechanisms.

Access AAPM&R’s popular Online Learning Portal, which features educational resources, including case studies, instructional videos and more on a variety of clinical and practice topics.



Online Learning Portal

home-page_subscription_logo

Online Education Subscription

24/7 access to our online educational resources through the end of your annual membership cycle. Check out what's included below!

step-lockup

STEP Certificate Programs

AAPM&R’s highly-regarded STEP Certificate Programs are designed by physiatrists for physiatrists and teach and assess important physiatric skills using a progressive, competency- based curriculum.

phyzforum-omc-fnl

PhyzForum

PhyzForum is an online physiatry community that allows you to engage with peers, ask advice, and share experiences. Participate in discussions to network, collaborate, and exchange best practices with your peers.

Annual Assembly
November 12-15

12310A-1936

The 2020 Annual Assembly is virtual! Join us from November 12-15 as we meet online to share best practices and support each other as we navigate a “new normal."

Critical Conversation Series

Thursday, October 1 at 6 pm (CT)

You're invited to participate in a series of discussions on racial equity, access and inclusion in today’s world. Join us for our next conversation on October 1 for AAPM&R's Diversity and Inclusion Journey. We will review efforts that led to the creation of the D&I strategic plan, unveil our new Principles of Inclusion and Engagement and share new initiatives on the horizon.

AAPM&R News

UPDATE: Voluntary Recall of Synvisc-One Lot 7RSL021

Dec 20, 2017

UPDATE (Jan. 2, 2018): No other Synvisc-One or SYNVISC lots are impacted by this voluntary recall. This voluntary product recall is isolated to one product lot within the US only and is at the physician, hospital, and wholesale/pharmacy level. Read this letter for further details and contact information.

Originally published on December 20, 2017:

On December 11, 2017, Sanofi Genzyme initiated a voluntary product recall for a single lot of Synvisc-One® (hylan G-F 20) lot 7RSL021 due to an ongoing investigation which revealed the presence of microbial contamination. The microbe is a common airborne organism and is a rare cause of human infections in both immunocompromised and immunocompetent patients. 

Use of this voluntarily recalled lot may result in a risk of infection. This lot was distributed October 25, 2017 through November 7, 2017 only in the US market. The most frequently reported adverse events in association with this lot are consistent with documented adverse events in the product label. This voluntary recall is being conducted with the knowledge of the US Food and Drug Administration. 

No other Synvisc-One or Synvisc lots are impacted by this voluntary recall. The voluntary recall is at the physician and wholesale/pharmacy level and is isolated to one product lot. 

Sanofi Genzyme is working with its distributors to ensure that all product in the specified lot is returned to the company. Sanofi Genzyme is committed to patient safety and to maintaining the highest product quality standards and we do not anticipate supply issues for Synvisc-One as a result of this voluntary product recall. 

For More Information: 

Health Care Providers should direct all medical and clinical questions to Sanofi Medical Information Services in the U.S. at 1-800-633-1610, option 1. 

Patient inquiries regarding this voluntary recall should be directed to Sanofi U.S. Customer Service at 1-800-633-1610 option 7 then 4. 

Patients who have experienced an adverse event or for Health Care Providers reporting an adverse event, all calls should be directed to Sanofi Adverse Event Reporting in the U.S. at 1-800-633-1610, option 2. 

General Questions about the voluntary recall should be directed to Sanofi U.S. Customer Service at 1-800-633-1610 option 7 then 4. 

For product return information related to the voluntary recalled Synvisc-One lot 7RSL021, please contact FedEx Supply Chain Solutions (GENCO) at 1-855-838-5782.

Physiatry News

UPDATE: Voluntary Recall of Synvisc-One Lot 7RSL021

Dec 20, 2017

UPDATE (Jan. 2, 2018): No other Synvisc-One or SYNVISC lots are impacted by this voluntary recall. This voluntary product recall is isolated to one product lot within the US only and is at the physician, hospital, and wholesale/pharmacy level. Read this letter for further details and contact information.

Originally published on December 20, 2017:

On December 11, 2017, Sanofi Genzyme initiated a voluntary product recall for a single lot of Synvisc-One® (hylan G-F 20) lot 7RSL021 due to an ongoing investigation which revealed the presence of microbial contamination. The microbe is a common airborne organism and is a rare cause of human infections in both immunocompromised and immunocompetent patients. 

Use of this voluntarily recalled lot may result in a risk of infection. This lot was distributed October 25, 2017 through November 7, 2017 only in the US market. The most frequently reported adverse events in association with this lot are consistent with documented adverse events in the product label. This voluntary recall is being conducted with the knowledge of the US Food and Drug Administration. 

No other Synvisc-One or Synvisc lots are impacted by this voluntary recall. The voluntary recall is at the physician and wholesale/pharmacy level and is isolated to one product lot. 

Sanofi Genzyme is working with its distributors to ensure that all product in the specified lot is returned to the company. Sanofi Genzyme is committed to patient safety and to maintaining the highest product quality standards and we do not anticipate supply issues for Synvisc-One as a result of this voluntary product recall. 

For More Information: 

Health Care Providers should direct all medical and clinical questions to Sanofi Medical Information Services in the U.S. at 1-800-633-1610, option 1. 

Patient inquiries regarding this voluntary recall should be directed to Sanofi U.S. Customer Service at 1-800-633-1610 option 7 then 4. 

Patients who have experienced an adverse event or for Health Care Providers reporting an adverse event, all calls should be directed to Sanofi Adverse Event Reporting in the U.S. at 1-800-633-1610, option 2. 

General Questions about the voluntary recall should be directed to Sanofi U.S. Customer Service at 1-800-633-1610 option 7 then 4. 

For product return information related to the voluntary recalled Synvisc-One lot 7RSL021, please contact FedEx Supply Chain Solutions (GENCO) at 1-855-838-5782.

Take the Next STEP in Your Ultrasound Education

step

AAPM&R's STEP Ultrasound Certificate Program is the premiere ultrasound training program—designed by physiatrists, for physiatrists. 

As the only formal, standardized training pathway available for honing and validating your ultrasound skill set, successful completion of the STEP Ultrasound Program will clearly demonstrate to your patients, fellow health care professionals, employers, and the medical facilities you work with that you are a competent professional, expertly trained in ultrasound. 

PhyzForum AAPM&R's Online Member Community